Please be aware that all information shared here at Canada Pharmacy has been medically reviewed and fact-checked for accuracy. These verifications are made by board-certified medical professionals who have the authority required to state that information related to medical conditions, symptoms, procedures and tests, and standard treatment protocols is valid and truthful. This is based on current guidelines and consensuses shared amongst medical professionals, and in representation of the latest research.
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Also Known as Competact
Actoplus Met (pioglitazone and metformin hydrochloride) is a combination medication that is used with diet and exercise to treat high blood sugar in adults with type 2 diabetes.
Actoplus Met comes in oral tablets that contain 15 mg pioglitazone/500 mg of metformin HCl and 15 mg pioglitazone/850 mg metformin HCl.
Take Actoplus Met exactly as your doctor has prescribed. If you have any questions or concerns, ask your doctor or pharmacist.
Your Actoplus Met dosage will depend on your current treatment regimen and may be adjusted based on response and tolerance. The dose should not exceed pioglitazone 45 mg and metformin 2550 mg by mouth daily.
Pioglitazone, a thiazolidinedione, and metformin, a biguanide, are the active ingredients in Actoplus Met. Povidone, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose 2910, polyethylene glycol 8000, titanium dioxide, and talc are the inactive ingredients.
Actoplus Met should not be given to patients with New York Heart Association Class III or IV heart failure.
Actoplus Met should not be given to patients with severe kidney problems.
Actoplus Met should not be given to patients who are allergic to pioglitazone, metformin, or to any of its other ingredients.
Actoplus Met should not be given to patients with diabetic ketoacidosis.
Actoplus Met has the following FDA Boxed Warnings:
The most common side effects associated with Actoplus Met include upper respiratory tract infection, swelling, diarrhea, headache, and weight gain. If any other side effects occur that become bothersome or persistent, call your doctor right away.
Actoplus Met. Lexington, MA: Takeda Pharmaceuticals America Inc.; 2020.